Arvinas получила историческое одобрение FDA для первого PROTAC-препарата и заключила сделку с Rigel Pharmaceuticals

On August 4, Arvinas Inc. (NASDAQ: ARVN ) reported second-quarter 2026 financial results and a corporate update that doubled as one of the more consequential updates in the company’s history. The clinical-stage biotech disclosed the first-ever FDA approval of a PROTAC, a heterobifunctional protein degrader, alongside a licensing deal that hands off commercial duties to another drugmaker. Revenue for the quarter came in at $249.7 million, up from $22.4 million a year earlier. Here is what the numbers and the pipeline update actually say. A Breakthrough Cashes In The headline event was the FDA’s approval of VEPPANU (vepdegestrant), an oral PROTAC estrogen receptor degrader, for adults with ER+/HER2-negative, ESR1-mutated advanced or metastatic breast cancer who progressed on at least one prior endocrine therapy. It marks the first FDA approval of a PROTAC therapy of any kind. Arvinas then licensed exclusive global development, manufacturing, and commercialization rights for VEPPANU to Rigel Pharmaceuticals, and the National Comprehensive Cancer Network added vepdegestrant to its breast cancer guidelines as a Category 2A option. That approval and the Rigel deal together produced $50.0 million in milestone revenue and $62.5 million in license revenue this quarter, plus $112.6 million tied to the original Pfizer collaboration agreement, most of it from recognizing $126.4 million in deferred revenue once the Rigel agreement closed. Beyond VEPPANU, Arvinas has three Phase 1 readouts expected over the next 12 months across ARV-393 in lymphoma, ARV-102 in Parkinson’s disease, and ARV-027 in muscle wasting, with early ARV-393 data already showing responses in both B- and T-cell lymphomas at doses below the predicted effective level. The company also unveiled preclinical data for ARV-6723, an HPK1 degrader that reversed T-cell exhaustion and boosted antitumor activity beyond existing checkpoint inhibitors in resistant tumor models, and for a pan-KRAS degrader program that outperformed a pan-RAS inhibitor in multiple solid tumor models. The Bill Is Still Due Turning a first-in-class approval into cash took real spending. Cash, cash equivalents, and marketable securities fell to $567.9 million as of June 30, from $685.4 million at the end of 2025, a $117.5 million drop over six months driven mostly by $114.3 million used in operations, even after netting out $35.0 million received under the Rigel agreement. Cost of license revenue, zero a year ago, hit $9.0 million this quarter because of Yale License Agreement obligations tied directly to the VEPPANU approval and the Rigel deal. G&A costs also crept up on the licensing side, with a $4.2 million rise in professional fees tied to the Pfizer agreement amendment and the Rigel transaction partly offsetting other savings. And Arvinas chose to out-license VEPPANU rather than build commercial infrastructure itself, the same path it says it plans to pursue for any expanded trials of ARV-806, its KRAS G12D program. Management’s own guidance points to cash lasting into the second half of 2028, meaning more capital raises or partnerships are likely still ahead of any of these earlier-stage programs reaching the market. Wall Street’s Mixed Signals Hedge fund ownership ticked up slightly, from 32 funds in the prior quarter to 33 now, a modest but positive shift in institutional interest. Short interest sits at 7.22% of float, a level that suggests a real but not overwhelming bear camp has built a position against the stock. That combination points to a market still working out how to price a company that just achieved a scientific first but continues to burn cash doing it. What Happens Next Arvinas closed the quarter having proven its degrader platform can clear the FDA, then immediately handed the commercial reins to a partner. The bulls have a widening pipeline with data catalysts stacked through 2027 and a licensing model that brings in cash without building a sales force. The bears can point to a $114.3 million operating burn and rising costs tied directly to that same licensing structure. For the pipeline bet to pay off, ARV-393, ARV-102, and ARV-027 need their upcoming readouts to hold up. READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In. Follow Insider Monkey on Google News. NASDAQ:ARVN Yahoo Finance Arvinas Inc. (NASDAQ:ARVN)